Generic and biosimilar medicines: quid?

Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market. This market entry is conditional on the approval of marketing authorization, pricing and reimbursement. Given that th...

Full description

Bibliographic Details
Main Author: Steven Simoens
Format: Article
Language:English
Published: SEEd Medical Publishers 2012-12-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/448

Similar Items